Lidocaine treatment in pediatric convulsive status epilepticus

Area of Science:

• Neurology
• Emergency Medicine
• Pharmacology

Background:

• Convulsive status epilepticus (CSE) is a life-threatening neurological emergency.
• Standard treatments include intravenous benzodiazepines, phenytoin, or barbiturates.
• The efficacy of lidocaine as an alternative or adjunctive therapy for CSE requires further investigation.

Purpose of the Study:

• To evaluate the effectiveness of lidocaine in patients with CSE who have not responded to first-line anticonvulsant therapies.
• To compare the response to lidocaine in patients with CSE of infectious versus non-infectious etiologies.
• To assess the safety and adverse reactions associated with lidocaine treatment in CSE.

Main Methods:

• Lidocaine was administered intravenously as a bolus (2 mg/kg) followed by an infusion (4 mg/kg/h) to 49 patients across 29 CSE episodes.
• Patients had previously failed to respond to diazepam, phenobarbital, and/or phenytoin.
• Outcomes were compared between patients with infectious and non-infectious causes of CSE.

Main Results:

• Lidocaine demonstrated a 44.4% overall effectiveness in treating CSE.
• A significant difference in response was observed, with infectious CSE cases responding better (37.9%) than non-infectious cases (6.8%; P < 0.05).
• Adverse reactions occurred in 10.3% of patients, including ventricular arrhythmia and seizure generalization.

Conclusions:

• Lidocaine appears to be a useful anticonvulsant for managing CSE, especially when CSE is infection-related.
• A favorable response to lidocaine was associated with a lower incidence of subsequent epilepsy.
• Larger studies are warranted to confirm these findings and establish lidocaine's role in CSE management.